Notícias Eulerpool Aclaris Therapeutics

Aclaris Therapeutics Eulerpool-AFX

Aclaris Therapeutics Notícias de ações

Aclaris Therapeutics é observado por muitos jornalistas e investidores em todo o mundo. As notícias mais recentes de Aclaris Therapeutics nós reunimos aqui.

• 18 de setembro ·

  Yahoo
  Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
• 18 de setembro ·

  TipRanks
  Aclaris Therapeutics’ ATI-2138: A Hold Rating Amidst Phase 2a Trials and Market Opportunity Assessment
• 17 de setembro ·

  Yahoo
  Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
• 17 de setembro ·

  TipRanks
  Aclaris Therapeutics (ACRS) Gets a Hold from H.C. Wainwright
• 17 de setembro ·

  Thefly.com
  Aclaris announces first patient dosed in Phase 2a trial of ATI-2138
• 10 de setembro ·

  Yahoo
  Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
• 19 de agosto ·

  TipRanks
  H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)
• 10 de agosto ·

  Yahoo
  Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
• 9 de agosto ·

  Yahoo
  Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations
• 9 de agosto ·

  TipRanks
  Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review